Coca-Cola has struggled to integrate its $5.6 billion purchase of BodyArmor with Powerade, which led to more “disruption in the short-term” than expected, according to CEO James Quincey.
Body Armor’s sales declined in the latest quarter.
The Atlanta-based Coca-Cola is optimistic that BodyArmor will eventually complement Powerade, its other big offering in the sports-drink category, as it aims to better compete against industry heavyweight, Pepsi-owned Gatorade.
BodyArmor’s purchase is the largest acquisition in Coca-Cola’s history.
In 2018, Coca-Cola first paid an undisclosed sum for a 15% share in BodyArmor, which had revenues of around $250 million.
That amount increased to more than $1 billion in 2021 when it acquired the remaining shares of brand to increase the variety of beverages it offers.
Through the use of coconut water, low sodium and high potassium levels, the lack of artificial colors, and the addition of sugar in place of high fructose corn syrup, the fast-growing, healthier sports drink gained popularity among consumers.
The purchase of BodyArmor by Coca-Cola led to a big bet that the beverage would play a key role in building out its liquid offerings and repositioning the business into a “total beverage company.”
Coca-Cola’s U.S. sports-drink market share had slipped in recent months. Still, the Coke chief remains optimistic this year will be a turning point for BodyArmor.


Russia Stocks End Flat as MOEX Closes Unchanged Amid Mixed Global Signals
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race
South Korea Exports Surge in January on AI Chip Demand, Marking Fastest Growth in 4.5 Years
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
India Budget 2026: Modi Government Eyes Reforms Amid Global Uncertainty and Fiscal Pressures
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
BOJ Policymakers Warn Weak Yen Could Fuel Inflation Risks and Delay Rate Action
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
LA28 Confirms Olympic Athletes Exempt from Trump’s Travel Ban
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 



